Catalyst Event
ABL Bio Inc (298380) · Other
From KRX Bio Technology Transfer Index (KBIOTT)
3/22/2026, 12:00:00 AM
Reorganization of R&D division to establish independent 'ADC Technology' and 'Antibody Discovery' teams on March 22, 2026. Strategic focus on high-growth ADC sector is expected to have a medium positive impact, scheduled.
Korean Translation
차세대 ADC 개발 가속화를 위한 R&D 조직 개편 및 부서 신설이 2026년 3월 22일 진행될 예정됨. 핵심 기술 집중 투자로 중간 수준의 긍정적 영향이 예상됨.
Related Recent Events
GC Cell Corporation (144510) · Earnings Release
The company reported a significant net loss for the full year 2025, primarily driven by a large-scale goodwill impairment of approximately KRW 220 billion related to the 2021 merger of its predecessor companies; 10% or more price impact expected.
3/24/2026, 12:00:00 AM
ABL Bio Inc (298380) · Other
ABL Bio Inc. to be added to the FTSE All-World Index on March 23, 2026. Index inclusion typically drives institutional buying, likely resulting in a low price impact, scheduled.
3/23/2026, 12:00:00 AM
Yuhan Corp (000100) · Other
The 103rd Annual General Meeting was held on 2026-03-20. Key resolutions included the approval of financial statements for fiscal year 2025 and the confirmation of a dividend of 600 KRW per common share.
3/20/2026, 12:00:00 AM
ABL Bio Inc (298380) · Other
Announcement of preclinical data presentation for ABL206 and ABL209 at AACR on March 19, 2026. Positive data at major conferences often boosts biotech valuations, estimated as a medium impact, scheduled.
3/19/2026, 12:00:00 AM
ABL Bio Inc (298380) · Other
U.S. FDA agreement on accelerated approval pathway for Givastomig (ABL111) on March 17, 2026. Accelerated pathways significantly shorten time-to-market, likely causing a high positive impact, scheduled.
3/17/2026, 12:00:00 AM